How would you modify dosing for a renally cleared drug in a patient with severe renal impairment?

How would you modify dosing for a renally cleared drug in a patient with severe renal impairment?

• A. Reduce the dose or extend the dosing interval to achieve similar AUC and trough levels.
• B. Increase the dose to compensate for decreased clearance.
• C. Switch to an intravenous infusion to bypass renal clearance.
• D. Assume unchanged exposure because hepatic clearance is unaffected.

Answer: (A)

When a drug is cleared mainly by the kidneys and renal function is severely reduced, overall clearance drops. This leads to higher systemic exposure (AUC) and can raise trough levels if dosing stays the same. To keep exposure similar to that in normal renal function, you would lower the dose or extend the dosing interval. This directly addresses the relationship AUC ≈ Dose/Cl: with clearance falling, reducing Dose or spreading out doses maintains the target AUC and prevents accumulation at troughs. Increasing the dose would worsen exposure, not correct it. Switching to an intravenous infusion does not bypass renal clearance—the drug is still eliminated by the kidneys and other routes after administration, so exposure would not be reliably maintained by simply changing the route. Assuming unchanged exposure because hepatic clearance is unaffected ignores that total clearance is the sum of all routes, and relief from renal impairment cannot be achieved by hepatic clearance alone.

When a drug is cleared mainly by the kidneys and renal function is severely reduced, overall clearance drops. This leads to higher systemic exposure (AUC) and can raise trough levels if dosing stays the same. To keep exposure similar to that in normal renal function, you would lower the dose or extend the dosing interval. This directly addresses the relationship AUC ≈ Dose/Cl: with clearance falling, reducing Dose or spreading out doses maintains the target AUC and prevents accumulation at troughs.

Increasing the dose would worsen exposure, not correct it. Switching to an intravenous infusion does not bypass renal clearance—the drug is still eliminated by the kidneys and other routes after administration, so exposure would not be reliably maintained by simply changing the route. Assuming unchanged exposure because hepatic clearance is unaffected ignores that total clearance is the sum of all routes, and relief from renal impairment cannot be achieved by hepatic clearance alone.